Is Inovio Pharma (NASDAQ:INO) moving to revert?


USD 2.01  0.04  1.95%   

As many millenniums are trying to avoid healthcare space, it makes sense to outline Inovio Pharma a little further and try to understand its current market patterns. As we have suggested previously, Inovio Pharma is beginning its slide as institutional investors shift to be more bearish due to the increased sector volatility. Inovio Pharma hyperactively responds to market trends. Plenty of the changes of the company stock price movements has been a rough indication of what is happening in the market overall. Persistent basic indicators of the company may entail signs of short-term price drift for institutional investors. The stock is still going through a very aggressive trading activities.
Published over three months ago
View all stories for Inovio Pharma | View All Stories
The company's average rating is Hold from 8 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Inovio Pharma market sentiment investors' perception of the future value of Inovio. Let us look at a few aspects of Inovio technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Inovio Pharma. In general, we focus on analyzing Inovio Pharma stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Inovio Pharma's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Inovio Pharma's intrinsic value. In addition to deriving basic predictive indicators for Inovio Pharma, we also check how macroeconomic factors affect Inovio Pharma price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Inovio Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Inovio Pharma in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inovio Pharma. Your research has to be compared to or analyzed against Inovio Pharma's peers to derive any actionable benefits. When done correctly, Inovio Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Inovio Pharma.

How important is Inovio Pharma's Liquidity

Inovio Pharma financial leverage refers to using borrowed capital as a funding source to finance Inovio Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Inovio Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Inovio Pharma's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Inovio Pharma, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by David Weiner of 11875 shares of Inovio Pharma subject to Rule 16b-3

Legal trades by Inovio Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Inovio insider trading alert for exercise of common stock option by David Weiner, the corporate stakeholder, on 11th of August 2022. This event was filed by Inovio Pharmaceuticals In with SEC on 2022-08-11. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Inovio Pharma has a beta of 2.4499. Let's try to break down what Inovio's beta means in this case. As returns on the market increase, Inovio Pharma returns are expected to increase less than the market. However, during the bear market, the loss on holding Inovio Pharma will be expected to be smaller as well. The beta indicator helps investors understand whether Inovio Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Inovio deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
The big decline in price over the last few months for Inovio Pharmamay raise some interest from institutional investors. The stock closed today at a share price of 1.73 on 4,496,573 in trading volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Inovio Pharma or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.17. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Inovio Pharma partners.

Is Inovio showing proof of lower volatility?

Latest treynor ratio indicator falls down to -0.29. Possible price upswing? Inovio Pharma is displaying above-average volatility over the selected time horizon. Investors should scrutinize Inovio Pharma independently to ensure intended market timing strategies are aligned with expectations about Inovio Pharma volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Inovio Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Inovio Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Inovio Pharma Implied Volatility

Inovio Pharma's implied volatility exposes the market's sentiment of Inovio Pharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inovio Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inovio Pharma stock will not fluctuate a lot when Inovio Pharma's options are near their expiration.

Our Final Perspective on Inovio Pharma

Whereas some firms in the biotechnology industry are either recovering or due for a correction, Inovio Pharma may not be performing as strong as the other in terms of long-term growth potentials. The bottom line, as of the 6th of June 2022, we believe that at this point, Inovio Pharma is risky with average odds of financial distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our latest 90 days recommendation on the company is Cautious Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Inovio Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to